Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.968 USD | -0.43% | -9.53% | -48.78% |
28/05 | Bionano Genomics Raises $18 Million From Private Debentures Placement | MT |
24/05 | Bionano Genomics, Inc. announced that it has received $18 million in funding | CI |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-48.78% | 6.69Cr | D+ | ||
+7.01% | 22TCr | B | ||
+11.01% | 19TCr | B- | ||
+19.20% | 14TCr | B- | ||
+30.79% | 11TCr | A- | ||
+1.48% | 6.46TCr | A- | ||
+13.95% | 5.24TCr | B+ | ||
-0.16% | 4.85TCr | B+ | ||
-6.20% | 3.8TCr | A | ||
+0.91% | 3.56TCr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BNGO Stock
- Ratings Bionano Genomics, Inc.